Urinary miRNA in Endometrial Cancer Study

Overview

This study is a prospective feasibility study with the addition of a retrospective cohort study on the the expression of microRNA in urine in endometrial cancer patients.

Full Title of Study: “Urinary microRNA Expression in Endometrial Cancer Patients – a Feasibility Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 26, 2020

Interventions

  • Diagnostic Test: Urinary miRNA
    • MiRNA detection in urine

Arms, Groups and Cohorts

  • Endometrial cancer patients
  • Control group
    • Patients without cancer

Clinical Trial Outcome Measures

Primary Measures

  • Accuracy of predictive value of miRNA test in detecting endometrial cancer
    • Time Frame: 6 months
    • To determine if miRNA can distinguish endometrial cancer patients from healthy patients

Secondary Measures

  • Correlation to final histology
    • Time Frame: 6 months
    • To determine how well miRNA correlates with final histology, i.e. can miRNA determine the subtype of endometrial cancer

Participating in This Clinical Trial

Inclusion Criteria

  • Confirmed diagnosis of endometrial cancer – Age: 18 years or older Exclusion Criteria:

  • Prior or coexisting other malignancies – Autoimmune disorders (other than diabetes mellitus)

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Royal Cornwall Hospitals Trust
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.